Skip to Content

SHP465 Approval Status

FDA Approved: No
Brand name: SHP465
Company: Shire plc
Treatment for: ADHD

SHP465 is a long-acting, triple-bead, mixed amphetamine salts formulation in development as a potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD).

Development Status and FDA Approval Process for SHP465

DateArticle
Jan 19, 2017U.S. FDA Acknowledges Receipt of Shire’s New Drug Application for SHP465 for ADHD
Jun 29, 2016Shire Announces Positive Topline Results of SHP465 Efficacy and Safety Study in Adults with ADHD

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide